» Articles » PMID: 24983977

Influence of Exclusive Enteral Nutrition Therapy on Visceral Fat in Patients with Crohn's Disease

Overview
Specialty Gastroenterology
Date 2014 Jul 2
PMID 24983977
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mesenteric fat plays an important role in the pathogenesis of Crohn's disease (CD), and a higher ratio of visceral fat area (VFA) to subcutaneous fat area (SFA) is related to complicated disease status. Exclusive enteral nutrition (EEN) is an effective treatment option for patients with CD, and the aims of this study were to assess the effects of EEN on abdominal fat in patients with CD.

Methods: Patient data were obtained from a prospectively maintained database. The SFA and VFA were measured in 38 patients with CD before and after 8-week EEN therapy, and the mesenteric fat index (MFI), defined as the ratio of VFA to SFA, was calculated. The correlations between MFI and CD activity index and C-reactive protein level were also evaluated.

Results: The median age of the patients in our study was 29 years, and the median duration of disease was 3.05 years. Both VFA (P = 0.029) and MFI (P = 0.021) were significantly decreased in patients after EEN, but no significant change was observed in SFA (P = 0.335). MFI was significantly correlated with CD activity index (r = 0.523, P = 0.001) and C-reactive protein (r = 0.634, P < 0.0001) in patients with active CD before EEN, although no positive correlations were observed in patients after EEN treatment.

Conclusions: EEN induction therapy was associated with a significant decrease in VFA in patients with CD, and MFI was significantly correlated with CD activity index and C-reactive protein in active CD. Thus, our data reveal additional beneficial therapeutic mechanisms of enteral nutrition treatment in CD.

Citing Articles

Association between body fat composition and disease duration, clinical activity, and intravenous corticosteroid-induced response in inflammatory bowel disease.

He S, Huang Y, Peng Y, Chai J, Chen K Lipids Health Dis. 2023; 22(1):106.

PMID: 37481662 PMC: 10363311. DOI: 10.1186/s12944-023-01874-4.


Serial Changes in Body Composition and the Association with Disease Activity during Treatment in Patients with Crohn's Disease.

Lee J, Kim K, Ko Y, Oh C, Kim B, Park S Diagnostics (Basel). 2022; 12(11).

PMID: 36428862 PMC: 9689369. DOI: 10.3390/diagnostics12112804.


Can visceral adipose tissue and skeletal muscle predict recurrence of newly diagnosed Crohn's disease in different treatments.

Zhang Z, Yu X, Fang N, Long X, Ruan X, Qiu J BMC Gastroenterol. 2022; 22(1):250.

PMID: 35585617 PMC: 9116006. DOI: 10.1186/s12876-022-02327-5.


Consistency of Trans-Abdominal and Water-Immersion Ultrasound Images of Diseased Intestinal Segments in Crohn's Disease.

Wang F, Numata K, Yonezawa H, Sato K, Ishii Y, Yaguchi K Diagnostics (Basel). 2020; 10(5).

PMID: 32365572 PMC: 7277370. DOI: 10.3390/diagnostics10050267.


Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn's disease: the Indian experience.

Sood A, Singh A, Sudhakar R, Midha V, Mahajan R, Mehta V Intest Res. 2020; 18(2):184-191.

PMID: 32092799 PMC: 7206340. DOI: 10.5217/ir.2019.00094.